Skip to main content

Table 1 Patient baseline characteristics (n = 16)

From: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Characteristic N (%)
Median age, years (range) 48 (31–78)
Sex
 Female 8 (50)
 Male 8 (50)
Race
 Caucasian 12 (75)
 Other 4 (25)
ECOG performance status
 0 3 (19)
 1 13 (81)
Hormonally functioning tumor
 Yes 10 (63)
 No 6 (38)
Median number of prior therapies (range) 2 (1–5)
  1. Abbreviation: ECOG Eastern Cooperative Oncology Group